185 related articles for article (PubMed ID: 37130759)
1. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma.
Corradi C; Lencioni G; Gentiluomo M; Felici A; Latiano A; Kiudelis G; van Eijck CHJ; Marta K; Lawlor RT; Tavano F; Boggi U; Dijk F; Cavestro GM; Vermeulen RCH; Hackert T; Petrone MC; Uzunoğlu FG; Archibugi L; Izbicki JR; Morelli L; Zerbi A; Landi S; Stocker H; Talar-Wojnarowska R; Di Franco G; Hegyi P; Sperti C; Carrara S; Capurso G; Gazouli M; Brenner H; Bunduc S; Busch O; Perri F; Oliverius M; Hegyi PJ; Goetz M; Scognamiglio P; Mambrini A; Arcidiacono PG; Kreivenaite E; Kupcinskas J; Hussein T; Ermini S; Milanetto AC; Vodicka P; Kiudelis V; Hlaváč V; Soucek P; Theodoropoulos GE; Basso D; Neoptolemos JP; Nóbrega Aoki M; Pezzilli R; Pasquali C; Chammas R; Testoni SGG; Mohelnikova-Duchonova B; Lucchesi M; Rizzato C; Canzian F; Campa D
J Med Genet; 2023 Oct; 60(10):980-986. PubMed ID: 37130759
[TBL] [Abstract][Full Text] [Related]
2. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling.
Endo Y; Fujimoto M; Ito N; Takahashi Y; Kitago M; Gotoh M; Hiraoka N; Yoshida T; Kitagawa Y; Kanai Y; Arai E
J Cancer Res Clin Oncol; 2021 May; 147(5):1341-1354. PubMed ID: 33635431
[TBL] [Abstract][Full Text] [Related]
4. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
[TBL] [Abstract][Full Text] [Related]
5. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma.
Pistoni L; Gentiluomo M; Lu Y; López de Maturana E; Hlavac V; Vanella G; Darvasi E; Milanetto AC; Oliverius M; Vashist Y; Di Leo M; Mohelnikova-Duchonova B; Talar-Wojnarowska R; Gheorghe C; Petrone MC; Strobel O; Arcidiacono PG; Vodickova L; Szentesi A; Capurso G; Gajdán L; Malleo G; Theodoropoulos GE; Basso D; Soucek P; Brenner H; Lawlor RT; Morelli L; Ivanauskas A; ; Kauffmann EF; Macauda A; Gazouli M; Archibugi L; Nentwich M; Loveček M; Cavestro GM; Vodicka P; Landi S; Tavano F; Sperti C; Hackert T; Kupcinskas J; Pezzilli R; Andriulli A; Pollina L; Kreivenaite E; Gioffreda D; Jamroziak K; Hegyi P; Izbicki JR; Testoni SGG; Zuppardo RA; Bozzato D; Neoptolemos JP; Malats N; Canzian F; Campa D
Carcinogenesis; 2021 Aug; 42(8):1037-1045. PubMed ID: 34216462
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
8. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk.
Ünal P; Lu Y; Bueno-de-Mesquita B; van Eijck CHJ; Talar-Wojnarowska R; Szentesi A; Gazouli M; Kreivenaite E; Tavano F; Małecka-Wojciesko E; Erőss B; Oliverius M; Bunduc S; Nóbrega Aoki M; Vodickova L; Boggi U; Giaccherini M; Kondrackiene J; Chammas R; Palmieri O; Theodoropoulos GE; Bijlsma MF; Basso D; Mohelnikova-Duchonova B; Soucek P; Izbicki JR; Kiudelis V; Vanella G; Arcidiacono PG; Włodarczyk B; Hackert T; Schöttker B; Uzunoglu FG; Bambi F; Goetz M; Hlavac V; Brenner H; Perri F; Carrara S; Landi S; Hegyi P; Dijk F; Maiello E; Capretti G; Testoni SGG; Petrone MC; Stocker H; Ermini S; Archibugi L; Gentiluomo M; Cavestro GM; Pezzilli R; Di Franco G; Milanetto AC; Sperti C; Neoptolemos JP; Morelli L; Vokacova K; Pasquali C; Lawlor RT; Bazzocchi F; Kupcinskas J; Capurso G; Campa D; Canzian F
Hum Genomics; 2024 Feb; 18(1):12. PubMed ID: 38308339
[TBL] [Abstract][Full Text] [Related]
10. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes.
Amato E; Barbi S; Fassan M; Luchini C; Vicentini C; Brunelli M; Malleo G; Scarpa A; Malpeli G
BMC Cancer; 2016 Jan; 16():11. PubMed ID: 26754001
[TBL] [Abstract][Full Text] [Related]
11. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk.
Giaccherini M; Farinella R; Gentiluomo M; Mohelnikova-Duchonova B; Kauffmann EF; Palmeri M; Uzunoglu F; Soucek P; Petrauskas D; Cavestro GM; Zykus R; Carrara S; Pezzilli R; Puzzono M; Szentesi A; Neoptolemos J; Archibugi L; Palmieri O; Milanetto AC; Capurso G; van Eijck CHJ; Stocker H; Lawlor RT; Vodicka P; Lovecek M; Izbicki JR; Perri F; Kupcinskaite-Noreikiene R; Götz M; Kupcinskas J; Hussein T; Hegyi P; Busch OR; Hackert T; Mambrini A; Brenner H; Lucchesi M; Basso D; Tavano F; Schöttker B; Vanella G; Bunduc S; Petrányi Á; Landi S; Morelli L; Canzian F; Campa D
Int J Cancer; 2023 Jul; 153(2):373-379. PubMed ID: 36451333
[TBL] [Abstract][Full Text] [Related]
12. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
13. Germline genetic variability in pancreatic cancer risk and prognosis.
Gentiluomo M; Canzian F; Nicolini A; Gemignani F; Landi S; Campa D
Semin Cancer Biol; 2022 Feb; 79():105-131. PubMed ID: 32818625
[TBL] [Abstract][Full Text] [Related]
14. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
[TBL] [Abstract][Full Text] [Related]
15. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of IRX4 is responsible for acceleration of cell growth in human pancreatic cancer.
Chakma K; Gu Z; Abudurexiti Y; Hata T; Motoi F; Unno M; Horii A; Fukushige S
Cancer Sci; 2020 Dec; 111(12):4594-4604. PubMed ID: 32894817
[TBL] [Abstract][Full Text] [Related]
17. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
Zheng-Lin B; Rainone M; Varghese AM; Yu KH; Park W; Berger M; Mehine M; Chou J; Capanu M; Mandelker D; Stadler ZK; Birsoy O; Jairam S; Yang C; Li Y; Wong D; Benhamida JK; Ladanyi M; Zhang L; O'Reilly EM
Mol Diagn Ther; 2022 Nov; 26(6):645-653. PubMed ID: 36178671
[TBL] [Abstract][Full Text] [Related]
18. Aberrant RNA Splicing Is a Primary Link between Genetic Variation and Pancreatic Cancer Risk.
Tian J; Chen C; Rao M; Zhang M; Lu Z; Cai Y; Ying P; Li B; Wang H; Wang L; Li Y; Huang J; Fan L; Cai X; Ning C; Li Y; Zhang F; Wang W; Jiang Y; Liu Y; Wang M; Li H; Huang C; Yang Z; Chang J; Zhu Y; Yang X; Miao X
Cancer Res; 2022 Jun; 82(11):2084-2096. PubMed ID: 35363263
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
20. SERPINB5 and AKAP12 - expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma.
Mardin WA; Petrov KO; Enns A; Senninger N; Haier J; Mees ST
BMC Cancer; 2010 Oct; 10():549. PubMed ID: 20939879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
